Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

RET M918T

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3	selpercatinib Sensitive: C3 – Early Trials selpercatinib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4	vandetanib Sensitive: C4 – Case Studies vandetanib Sensitive : C4
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4
RET M918T	Thyroid Gland Carcinoma	RET M918T	Thyroid Gland Carcinoma	XMD15-44 Sensitive: D – Preclinical XMD15-44 Sensitive : D	XMD15-44 Sensitive: D – Preclinical XMD15-44 Sensitive : D
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	AMG 706 Resistant: D – Preclinical AMG 706 Resistant : D	AMG 706 Resistant: D – Preclinical AMG 706 Resistant : D
RET M918T	Thyroid Gland Carcinoma	RET M918T	Thyroid Gland Carcinoma	HG-6-63-01 Sensitive: D – Preclinical HG-6-63-01 Sensitive : D	HG-6-63-01 Sensitive: D – Preclinical HG-6-63-01 Sensitive : D
RET M918T	Thyroid Gland Papillary Carcinoma	RET M918T	Thyroid Gland Papillary Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D
RET M918T	Thyroid Gland Carcinoma	RET M918T	Thyroid Gland Carcinoma	ALW-II-41-27 Sensitive: D – Preclinical ALW-II-41-27 Sensitive : D	ALW-II-41-27 Sensitive: D – Preclinical ALW-II-41-27 Sensitive : D